
Qiagen N.V (QGEN) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
483.5M
Gross Profit
308.7M
63.85%
Operating Income
125.2M
25.89%
Net Income
90.8M
18.77%
EPS (Diluted)
$0.41
Balance Sheet Metrics
Total Assets
5.5B
Total Liabilities
2.1B
Shareholders Equity
3.4B
Debt to Equity
0.63
Cash Flow Metrics
Operating Cash Flow
190.3M
Free Cash Flow
95.5M
Revenue & Profitability Trend
Qiagen N.V Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 2.0B | 2.0B | 2.1B | 2.3B | 1.9B |
Cost of Goods Sold | 1.0B | 731.6M | 757.0M | 800.8M | 637.6M |
Gross Profit | 967.4M | 1.2B | 1.4B | 1.5B | 1.2B |
Gross Margin % | 48.9% | 62.8% | 64.7% | 64.4% | 65.9% |
Operating Expenses | |||||
Research & Development | 193.5M | 198.5M | 189.9M | 190.0M | 149.1M |
Selling, General & Administrative | 564.4M | 579.2M | 603.9M | 584.5M | 525.4M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 757.9M | 777.7M | 793.8M | 774.4M | 674.4M |
Operating Income | 199.9M | 445.2M | 576.2M | 657.8M | 537.5M |
Operating Margin % | 10.1% | 22.7% | 26.9% | 29.2% | 28.7% |
Non-Operating Items | |||||
Interest Income | 68.0M | 79.0M | 32.8M | 9.6M | 10.0M |
Interest Expense | 43.8M | 53.4M | 58.4M | 54.5M | 71.3M |
Other Non-Operating Income | -102.9M | -41.0M | -38.0M | 12.9M | -36.7M |
Pre-tax Income | 121.1M | 429.8M | 512.6M | 625.8M | 439.5M |
Income Tax | 37.6M | 88.5M | 89.4M | 113.2M | 80.3M |
Effective Tax Rate % | 31.0% | 20.6% | 17.4% | 18.1% | 18.3% |
Net Income | 83.6M | 341.3M | 423.2M | 512.6M | 359.2M |
Net Margin % | 4.2% | 17.4% | 19.8% | 22.8% | 19.2% |
Key Metrics | |||||
EBITDA | 470.4M | 723.9M | 824.1M | 923.0M | 866.8M |
EPS (Basic) | $0.39 | $1.55 | $1.92 | $2.33 | $0.33 |
EPS (Diluted) | $0.38 | $1.53 | $1.90 | $2.28 | $0.32 |
Basic Shares Outstanding | 216435138 | 221301620 | 220749690 | 220261742 | 221574190 |
Diluted Shares Outstanding | 216435138 | 221301620 | 220749690 | 220261742 | 221574190 |
Income Statement Trend
Qiagen N.V Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 663.6M | 668.1M | 730.7M | 880.5M | 598.0M |
Short-term Investments | 489.4M | 389.7M | 687.6M | 184.8M | 117.2M |
Accounts Receivable | 349.3M | 381.9M | 323.8M | 362.1M | 380.5M |
Inventory | 279.3M | 398.4M | 358.0M | 327.5M | 291.2M |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 2.0B | 2.1B | 2.4B | 2.1B | 1.6B |
Non-Current Assets | |||||
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
Goodwill | 5.2B | 5.5B | 5.2B | 5.3B | 5.5B |
Intangible Assets | 303.8M | 526.8M | 544.8M | 627.4M | 726.2M |
Long-term Investments | 3.2M | 3.1M | 131.4M | 190.4M | 379.1M |
Other Non-Current Assets | 243.8M | 197.0M | 202.9M | 303.4M | 235.7M |
Total Non-Current Assets | 3.7B | 4.0B | 3.9B | 4.0B | 4.2B |
Total Assets | 5.7B | 6.1B | 6.3B | 6.1B | 5.9B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 83.3M | 84.2M | 98.7M | 101.2M | 118.2M |
Short-term Debt | 77.8M | 610.2M | 411.8M | 869.7M | 66.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 113.2M | 118.0M | 192.2M | 257.6M | 119.3M |
Total Current Liabilities | 543.6M | 1.1B | 974.5M | 1.5B | 572.2M |
Non-Current Liabilities | |||||
Long-term Debt | 1.3B | 921.8M | 1.5B | 1.1B | 1.9B |
Deferred Tax Liabilities | - | - | - | 37.6M | 39.2M |
Other Non-Current Liabilities | 240.6M | 207.4M | 218.0M | 246.9M | 186.7M |
Total Non-Current Liabilities | 1.6B | 1.2B | 1.8B | 1.5B | 2.5B |
Total Liabilities | 2.1B | 2.3B | 2.8B | 3.1B | 3.1B |
Equity | |||||
Common Stock | 2.6M | 2.7M | 2.7M | 2.7M | 2.7M |
Retained Earnings | 2.4B | 2.5B | 2.2B | 1.8B | 1.3B |
Treasury Stock | 74.9M | 133.0M | 160.2M | 189.7M | 118.3M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 3.6B | 3.8B | 3.5B | 3.1B | 2.8B |
Key Metrics | |||||
Total Debt | 1.4B | 1.5B | 1.9B | 2.0B | 1.9B |
Working Capital | 1.4B | 1.1B | 1.4B | 592.1M | 1.1B |
Balance Sheet Composition
Qiagen N.V Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 83.6M | 341.3M | 423.2M | 512.6M | 359.2M |
Depreciation & Amortization | 203.3M | 205.3M | 208.4M | 214.9M | 205.0M |
Stock-Based Compensation | 43.6M | 47.1M | 49.5M | 38.4M | 40.9M |
Working Capital Changes | 129.9M | -135.8M | -73.0M | -72.2M | -51.2M |
Operating Cash Flow | 464.1M | 506.5M | 654.9M | 726.3M | 601.3M |
Investing Activities | |||||
Capital Expenditures | -167.2M | -149.7M | -129.2M | -189.9M | -132.8M |
Acquisitions | 0 | -149.5M | -63.7M | 0 | -237.7M |
Investment Purchases | -688.4M | -979.3M | -1.4B | -400.3M | -49.8M |
Investment Sales | 585.0M | 1.3B | 883.1M | 359.6M | 206.9M |
Investing Cash Flow | -245.2M | -74.6M | -706.7M | -185.8M | -271.8M |
Financing Activities | |||||
Share Repurchases | -292.1M | 0 | 0 | -100.0M | -64.0M |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 494.2M | 0 | 371.5M | 0 | 497.6M |
Debt Repayment | -601.5M | -436.8M | -480.0M | -41.3M | -592.5M |
Financing Cash Flow | -422.9M | -470.6M | -125.8M | -150.4M | -174.0M |
Free Cash Flow | 502.3M | 296.7M | 565.9M | 432.5M | 153.6M |
Net Change in Cash | -203.9M | -38.7M | -177.6M | 390.1M | 155.4M |
Cash Flow Trend
Qiagen N.V Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
27.51
Forward P/E
20.31
Price to Book
2.88
Price to Sales
4.94
PEG Ratio
-0.18
Profitability Ratios
Profit Margin
18.30%
Operating Margin
25.49%
Return on Equity
10.81%
Return on Assets
9.01%
Financial Health
Current Ratio
1.61
Debt to Equity
42.31
Beta
0.64
Per Share Data
EPS (TTM)
$1.69
Book Value per Share
$16.17
Revenue per Share
$9.41
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
qgen | 10.2B | 27.51 | 2.88 | 10.81% | 18.30% | 42.31 |
Thermo Fisher | 184.1B | 28.20 | 3.64 | 13.42% | 15.24% | 69.62 |
Danaher | 147.0B | 43.70 | 2.82 | 6.68% | 14.21% | 35.45 |
Agilent Technologies | 36.0B | 29.29 | 5.59 | 19.88% | 17.97% | 56.42 |
Idexx Laboratories | 35.6B | 53.75 | 35.55 | 64.87% | 24.41% | 84.81 |
Iqvia Holdings | 32.4B | 27.61 | 5.61 | 19.79% | 7.88% | 272.12 |
Financial data is updated regularly. All figures are in the company's reporting currency.